The Human Tissue Authority (HTA) has published licence fee levels for the 2020/21 business year.
The new licence fees come into effect from 1 April 2020, with an increase of 4% on the previous year’s fees.
Background to HTA licence fees
After taking account of all other income sources, we are required to generate £3.85m in income from licence fees in 2020/21.
In line with previous years of making efficiencies, holding budgets steady and absorbing new work, we have limited the increase to fees to cover the cost inflation pressures anticipated in the next financial year.
Changes to this year’s fees
There are two amendments to the fees model for the 2020/21 financial year as follows:
- a revised fee for satellite sites that are undertaking post mortems; and
- a new temporary fixed period licence for activity that will be limited to a duration of no more than 6 months.
The 2020/21 fees have been increased by 4% which takes account of the rate of CPI in August when the fees were proposed and, in line with a number of other public sector bodies, the requirement to pay an additional 2.2% in employer pension contributions.
This year we undertook a detailed fees review that resulted in some small changes but no significant change to our fee structure. However, we are mindful that our operating landscape is changing, which affects our licensing and regulatory processes as well as the establishments across all sectors. Over the coming twelve months, we will be working with stakeholders to look at our approach to Third Party Arrangements as well as other emerging regulatory areas.
Any proposals for a reviewed fees model will be developed in consultation with those affected and we will announce further information to our stakeholders as work moves forward.